In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas

Neuro-Oncology

Volumn 9, Issue 2, 2007, Pages 82-88

  Entin Meer, Michal ^a   Yang, Xiaodong ^a   VandenBerg, Scott R ^b   Lamborn, Kathleen R ^a   Nudelman, Abraham ^c   Rephaeli, Ada ^d   Haas Kogan, Daphne Adele ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAR ILAN UNIVERSITY   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

H2AX phosphorylation; AN 9; Glioma; Histone deacetylase inhibitor; Radiation; Temozolomide

Indexed keywords

BUTYRIC ACID DERIVATIVE; DOUBLE STRANDED DNA; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; PIVALOYLOXYMETHYL BUTYRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; RADIATION RESPONSE; TREATMENT DURATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BUTYRATES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME INHIBITORS; GLIOMA; HISTONE DEACETYLASES; HUMANS; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 34147206651     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2006-032     Document Type: Article

References (19)

1. Blaheta, R.A., Michaelis, M., Driever, P.H., and Cinatl, J., Jr. (2005) Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies. Med. Res. Rev. 25, 383-397.
2. Butler, L.M., Agus, D.B., Scher, H.I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H.T., Rifkind, R.A., Marks, P.A., and Richon, V.M. (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 20, 5165-5170.
3. Camphausen, K., Cerna, D., Scott, T., Sproull, M., Burgan, W.E., Cerra, M.A., Fine, H., and Tofilon, P.J. (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer 114, 380-386.
4. Chakravarti, A., Erkkinen, M.G., Nestler, U., Stupp, R., Metha, M., Aldape, K., Gilbert, M.R., Black, P.M. and Loeffler, J.S. (2006) Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin. Cancer Res. 12, 4738-4746.
5. Cutts, S.M., Rephaeli, A., Nudelman, A., Hmelnitsky, I., and Phillips, D.R. (2001) Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 61, 8194-8202.
6. Dehdashti, A.R., Hegi, M.E., Regli, L., Pica, A., and Stupp, R. (2006) New trends in the medical management of glioblastoma multiforme: The role of temozolmide chemotherapy. Neurosurg. Focus 20, E6.
7. Entin-Meer, M., Rephaeli, A., Yang, X., Nudelman, A., Vandenberg, S.R., and Haas-Kogan, D.A. (2005) Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol. Cancer Ther. 4, 1952-1961.
8. Hussaini, I.M., Carpenter, J.E., Redpath, G.T., Sando, J.J., Shaffrey, M.E., and Vandenberg, S.R. (2002) Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation. Neuro-Oncology 4, 9-21.
9. Munshi, A., Kurland, J.F., Nishikawa, T., Tanaka, T., Hobbs, M.L., Tucker, S.L., Ismail, S., Stevens, C., and Meyn, R.E. (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11, 4912-4922.
10. Nudelman, A., Ruse, M., Aviram, A., Rabizadeh, E., Shaklai, M., Zimrah, Y., and Rephaeli, A. (1992) Novel anticancer prodrugs of butyric acid. J. Med. Chem. 35, 687-694.
11. Olive P.L., and Banath, J.P. (2004) Phosphorylation of histone H2AX as a measure of radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 58, 331-335.
12. Patnaik, A., Rowinsky, E.K., Villalona, A., Hammond, L.A., Britten, C.D., Siu, L.L., Goetz, A., Felton, S.A., Burton, S., Valone, F.H., and Eckhardt, S.G. (2002) A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 8, 2142-2148.
13. Prakash S., Foster, B.J., Meyer, M., Wozniak, A., Heilbrun, L.K., Flaherty, L., Zalupsky, M., Radulovic, L., Valdivieso, M., and LoRusso, P.M. (2001) Chronic oral administration of CI-994: A phase 1 study. Invest. New Drugs 19, 1-11.
14. Reid, T., Valone, F., Lipera, W., Irwin, D., Paroly, W., Natale, R., Sreedharan, S., Keer, H., Lum, B., Scappaticci, F., and Bhatnagar, A. (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45, 381-386.
15. Rephaeli, A., Blank-Porat, D., Tarasenko, N., Entin-Meer, M., Levovich, I., Cutts, S.M., Phillips, D.R., Malik, Z., and Nudelman, A. (2005) In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int. J. Cancer 116, 226-235.
16. Rephaeli, A., Entin-Meer, M., Angel, D., Tarasenko, N., Gruss-Fischer, T., Bruachman, I., Phillips, D.R., Cutts, S.M., Haas-Kogan, D., and Nudelman, A. (2006) The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Invest. New Drugs 24, 383-392.
17. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U. S. A. 96, 4592-4597.
18. Tang, X.X., Robinson, M.E., Riceberg, J.S., Kim, D.Y., Kung, B., Titus, T.B., Hayashi, S., Flake, A.W., Carpentieri, D., and Ikegaki, N. (2004) Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin. Cancer Res. 10, 5837-5844.
19. Zhang, Y., Jung, M., Dritschilo, A., and Jung M. (2004) Enchancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat. Res. 161, 667-674.